The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Dec. 18, 6:00 PM

Slide #13. Agios Pharmaceuticals, Inc. Secondary Offering

Company: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Date announced: 12/9/2014
Shares Offered: 1,986,455
Date of Pricing: 12/10/2014
Price Per Share: $110.75
Secondary Offering Details: Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $175 million of its common stock in an underwritten public offering. Agios also intends to grant the underwriters a 30-day option to purchase from it up to an additional $26.3 million of shares. All of the shares in the offering are to be sold by Agios. The proceeds of the offering are expected to be used to fund the company's clinical and research development activities. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. - updated 12/11 -Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 1,986,455 shares of common stock at a price to the public of $110.75 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $220 million. All of the shares in the offering are to be sold by Agios. Agios has also granted the underwriters a 30-day option to purchase up to an additional 297,968 shares of common stock on the same terms and conditions. Closing of the offering is expected to occur on or about December 16, 2014, subject to customary closing conditions.

Agios Pharmaceuticals is a biopharmaceutical company engaged in the field of cancer metabolism and inborn errors of metabolism. Co.'s lead product candidates are AG-221 and AG-120, which target mutant isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively. AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein for the treatment of patients with cancers that harbor IDH2 mutations, including those with acute myelogenous leukemia. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations.
Open the AGIO Page at The Online Investor »

Company Name:  Agios Pharmaceuticals Inc
Website:  www.agios.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding AGIO:  19
Total Market Value Held by ETFs:  $203.35M
Total Market Capitalization:  $3.73B
% of Market Cap. Held by ETFs:  5.46%
 

Open the AGIO Page at The Online Investor (in a new window) »

December 18, 2014    6:00 PM Eastern
Quotes delayed 20 minutes



Buy (3.33 out of 4)
65th percentile
(ranked higher than approx. 65% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.